A key problem is the ability of glioma stem cells to regenerate tumors after treatment and resist conventional therapies, making them a primary reason for treatment failure. Recent discoveries ...

The Brain Prize 2025 went to neuro-oncologists Michelle Monje and Frank Winkler for pioneering the field of cancer n.

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation. Stem cell-like glioma ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...